Beta-amyloid 42 peptide (Aβ42)

Beta-amyloid 42 peptide (Aβ42) is a 42–amino acid intrinsically disordered peptide generated from the proteolytic cleavage of the amyloid precursor protein (APP) by β- and γ-secretases[1][5][7]. Aβ42 has a greater tendency than its shorter counterpart (Aβ40) to aggregate into oligomers and fibrils, which are the principal components of amyloid plaques found in the brains of patients with Alzheimer’s disease[1][3][10]. Aβ42 aggregation is neurotoxic and contributes to synaptic dysfunction, neuronal loss, and progression of neurodegenerative pathology[1][9][10]. It is a major therapeutic target in Alzheimer’s disease, with multiple antibodies and small molecules in clinical development to block its aggregation, enhance clearance, or neutralize its toxic effects[5][7]. Detection of Aβ42 levels and its aggregation forms in cerebrospinal fluid or brain is used as a clinical biomarker for Alzheimer’s diagnosis and monitoring[5][7]. While Aβ42-directed therapies have advanced, challenges remain due to limited clinical efficacy, adverse effects, and incomplete understanding of the relationship between amyloid reduction and cognitive outcomes[5].

Other names

Beta-amyloid peptide (1–42)Amyloid beta (1–42)Aβ1-42A beta 42β-Amyloid (1–42)Amyloid A-peptide (1–42)An1792

Immunotherapy: Antibody binding and clearance of aggregated or soluble Aβ42; Inhibition of oligomerization or fibril formation; Direct disruption of amyloid plaques; Neutralization of neurotoxicity